Current Report Filing (8-k)
October 31 2013 - 9:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
October 31, 2013
HARVARD
APPARATUS REGENERATIVE TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-35853 |
45-5210462 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
84 October Hill Road, Holliston, MA |
01746 |
(Address of principal executive offices) |
(Zip Code) |
Registrant's telephone number, including
area code: (774) 233-7300
________________________________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
Item 8.01 Other Events.
On October 31, 2013, Harvard Bioscience, Inc. ("HBIO"),
the parent of Harvard Apparatus Regenerative Technology, Inc. (“HART”), issued a press release announcing its financial
results for the three and nine months ended September 30, 2013. The press release is furnished as Exhibit 99.1 and incorporated
herein by reference.
HBIO has also scheduled a conference call to discuss HBIO's
third quarter financial results for October 31, 2013 at 11:00 AM ET. Participating in the call will be Jeffrey A. Duchemin, Chief
Executive Officer; David Green, President; Tom McNaughton, Chief Financial Officer; and Robert Gagnon, Executive Vice President-Finance,
each of HBIO. In addition to discussing the third quarter financial results, management of HBIO expects to discuss the spin-off
of HART, and HBIO's business strategies. Management of HBIO may also answer questions concerning business and financial developments
and trends, and other matters affecting the company. Some of the information to be presented on the call or provided in response
to questions may contain information that has not previously been disclosed by HBIO or HART.
The conference call will be simultaneously broadcast over the
Internet and can be accessed through the Harvard Bioscience, Inc. website. To listen to the conference call, log on to the website
at www.harvardbioscience.com and click on the Earnings Call icon. Financial and other statistical
information presented on the call, including the earnings release, will also be available on the investor relations section of
the HBIO website. Click on the investor relations button and then click on the press release or webcast icon, as appropriate. If
you are unable to listen to the live webcast, the call will be archived in the investor relations section of the HBIO website.
The live conference call is also accessible by dialing toll-free 877-303-7611, or toll 970-315-0445, and referencing the pass code
of "89708444". A replay of this conference call will be available from approximately 2:00 PM ET on October 31, 2013 through
November 9, 2013 and will be accessible by dialing toll-free 855-859-2056, or toll 404-537-3406, and referencing the pass code
of "89708444".
The information in this Item 2.02 and Item 8.01 of this Current
Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number |
|
Title |
|
|
99.1 |
Press release of Harvard Bioscience, Inc. issued on October
31, 2013.
Incorporated by reference to Exhibit 99.1 of the Form 8-K filed
with the SEC on October 31, 2013. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
HARVARD
APPARATUS REGENERATIVE
TECHNOLOGY, INC.
|
|
|
(Registrant) |
October
31, 2013
(Date) |
|
/s/
THOMAS MCNAUGHTON |
|
|
Thomas McNaughton
Chief Financial Officer & Principal Accounting
Officer |
INDEX TO EXHIBITS
Exhibit
Number |
|
Title |
|
|
99.1 |
Press release of Harvard Bioscience, Inc. issued on October
31, 2013.
Incorporated by reference to Exhibit 99.1 of the Form 8-K filed
with the SEC on October 31, 2013. |
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From May 2024 to Jun 2024
Biostage (QB) (USOTC:BSTG)
Historical Stock Chart
From Jun 2023 to Jun 2024